Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1a receptor by introduction of alkoxy groups

Chemical and Pharmaceutical Bulletin

Volumn 51, Issue 9, 2003, Pages 1075-1080

  Shimada, Yoshiaki ^a   Taniguchi, Nobuaki ^a   Matsuhisa, Akira ^a   Yatsu, Takeyuki ^a   Tahara, Atsuo ^a   Tanaka, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Alkoxy group; Arginine vasopressin antagonist; V1a receptor selective

Indexed keywords

4' [[4,4 DIFLUORO 5 [(4 DIMETHYLAMINOPIPERIDINO)CARBONYLMETHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 BENZOAZEPIN 1 YL]CARBONYL] 2 ETHOXYBENZANILIDE; 4' [[4,4 [(4,4 DIFLUORO 5 MORPHOLINO)CARBAMOYLETHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 BENZOAZEPIN 1 YL]CARBONYL] 2 ETHOXYBENZANILIDE; ARGIPRESSIN RECEPTOR; CARBENE; MORPHOLINE DERIVATIVE; PIPERIDINE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; 4' ((4,4 DIFLUORO 5 METHYLIDENE 2,3,4,5 TETRAHYDRO 1H 1 BENZOAZEPIN 1 YL)CARBONYL)BENZANILIDE; 4'-((4,4-DIFLUORO-5-METHYLIDENE-2,3,4,5-TETRAHYDRO-1H-1-BENZOAZEPIN-1-YL)CARBONYL)BENZANILIDE; ACETIC ACID; ANILIDE; ARGIPRESSIN; AZEPINE DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; VASOPRESSIN RECEPTOR;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; RECEPTOR AFFINITY; ANIMAL; BLOOD PRESSURE; CELL MEMBRANE; CHEMISTRY; CHO CELL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HAMSTER; HUMAN; KIDNEY; LIVER; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ACETIC ACID; ANILIDES; ANIMALS; ARGININE VASOPRESSIN; AZEPINES; BLOOD PRESSURE; CELL MEMBRANE; CHEMISTRY, PHYSICAL; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDICATORS AND REAGENTS; KIDNEY; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; RATS; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2142857793     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.51.1075     Document Type: Article

References (13)

1. Michel R. H., Kirk C. J., Billah M. M., Biochem. Soc. Trans., 7, 861-865 (1979).
2. Jard S., Kidney Int., Supp., 26, 38-42 (1988).
3. Sugimoto T., Saito M., Mochizuki S., Watanabe Y., Hashimoto S., Kawashima H., J. Biol. Chem., 269, 27088-27092 (1994).
4. Yatsu T., Tomura T., Tahara A., Wada K., Tsukada J., Uchida W., Tanaka A., Takenaka T., Eur. J. Pharmacol., 321, 225-230 (1997).
5. Matsuhisa A., Tanaka A., Kikuchi K., Shimada Y., Yatsu T., Yanagisawa I., Chem. Pharm. Bull., 45, 1870-1874 (1997).
6. Matsuhisa A., Koshio H., Sakamoto K., Taniguchi N., Yatsu T., Tanaka A., Chem. Pharm. Bull., 46, 1566-1579 (1998).
7. Matsuhisa A., Kikuchi K., Sakamoto K., Yatsu T., Tanaka A., Chem. Pharm. Bull., 47, 329-339 (1999).
8. Matsuhisa A., Taniguchi N., Koshio H., Yatsu T., Tanaka A., Chem. Pharm. Bull., 48, 21-31 (2000).
9. Shimada Y., Taniguchi N., Matsuhisa A., Sakamoto K., Yatsu T., Tanaka A., Chem. Pharm. Bull., 48, 1644-1651 (2000).
10. Ogawa H., Yamamura Y., Miyamoto H., Kondo K., Yamashita H., Nakaya K., Chihara T., Mori T., Tominaga M., Yabuuchi Y., J. Med. Chem., 36, 2011-2017 (1993).
11. Serradeil-Li Gal C., Wagnon J., Garcia C., Lacour C., Guiraudou P., Christophe B., Villanova G., Nisato D., Maffrand J. P., Le Fur G., Guillon G., Cantau B., Barberis C., Trueba M., Ala Y., Jard S., J. Clin. Invest., 92, 224-231 (1993).
12. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukada J., Takanashi M., Yatsu T., Uchida W., Tanaka A., J. Pharmacol. Exp. Ther., 282, 301-308 (1997).
13. Tahara A., Saito M., Sugimoto T., Tomura Y., Wada K., Kusayama T., Tsukada J., Ishii N., Yatsu T., Uchida W., Tanaka A., Br. J. Pharmacol., 125, 1463-1470 (1998).